This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
MBNL1 / Muscleblind-like protein 1 · IHC design guide
Design Immunohistochemistry for MBNL1
Assess nuclear MBNL1 staining in paraffin sections using tissue patterns reported by HPA (HPA tissue IHC). Use high staining in cerebellar molecular-layer cells and undetected staining in adipocytes to plan controls and interpret results (HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
MBNL1 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Nuclear tissue staining; cytoplasmic location also annotated (HPA tissue IHC; UniProt) | |
| Staining pattern | Nuclear staining in most tissues (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet A02309-1) | |
| Positive control | Cerebellum+4 more · see all | |
| Negative control | Adipose tissue+2 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across paraffin sections. (standard IHC practice; not target-specific) | |
| Caveat | Skeletal myocytes may lack staining despite reported muscle expression (HPA tissue IHC; UniProt) | |
| Regulation | Higher during myoblast differentiation (UniProt) | |
| Isoform / epitope | 7 isoforms; antibody epitope coverage is unspecified (UniProt; datasheet A02309-1) |
Section 1
Recommended MBNL1 IHC & IF Protocols
The catalog antibody’s IHC-P protocol is accompanied by published MBNL1 IHC methods for transplanted tPVAT, human brain and glioblastoma, and intestinal tissue (PMC8698607; PMC7642170; PMC13297613).
| Sample | Paraffin-embedded human thyroid cancer tissue; fixative not specified (datasheet A02309-1) |
| Fixation | Image fixative and duration unreported (datasheet A02309-1); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet A02309-1); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet A02309-1) |
| Primary antibody | Rabbit anti-MBNL1, 2-5μg/ml (datasheet A02309-1) |
| Primary incubation | Overnight at 4 °C (datasheet A02309-1) |
| Detection | HRP-conjugated secondary, DAB chromogen (datasheet A02309-1) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | MBNL1-positive staining in cells in molecular layer of cerebellum (HPA tissue IHC: High). HPA tissue profile: Nuclear expression in most tissues. No signal in the no-primary control. |
💡Decision noteFor the catalog antibody, start with heat-mediated EDTA retrieval at pH 8.0 (datasheet A02309-1); adapt the published methods to the sample and antibody used.
Section 2
What Is the Expected MBNL1 Staining Pattern?
MBNL1 is mainly nuclear in tissue IHC, with nuclear expression across most tissues (HPA: Enhanced tissue reliability; medium consistency with RNA). High staining is reported in cerebellar molecular layer cells, nasopharyngeal respiratory epithelial cells, skin arrector pili muscle cells, and spermatogonia (HPA: tissue IHC). Cytoplasmic localization is also possible (UniProt Q9NR56: nucleus, cytoplasm, cytoplasmic granule). MBNL1 has no transmembrane segment (UniProt Q9NR56: topology).
| Distinct nuclear staining in the expected cells, strongest in an HPA high-staining tissue. | This fits the reported tissue pattern (HPA: nuclear expression in most tissues; High in the listed cell populations). Compare nuclei within the same section and judge cell identity from morphology and counterstain. HPA’s Enhanced tissue reliability still carries medium consistency between antibody staining and RNA expression (HPA: tissue IHC reliability). |
| Predominantly membranous or extracellular staining, with little nuclear signal. | This is discordant with the expected IHC compartment (HPA: nuclear expression in most tissues) and with the lack of a transmembrane segment or signal peptide (UniProt Q9NR56: topology, processing). Treat it as a possible staining artefact and review the negative control and tissue morphology before assigning MBNL1 positivity. |
| Strong staining in a cell population reported as not detected, while expected nuclei are weak. | For example, HPA reports no staining in adipocytes or spleen red-pulp cells (HPA: tissue IHC). Consider antibody cross-reactivity or endogenous chromogenic detection activity as possibilities (general IHC practice). A discordant cell pattern alone does not establish which cause applies; compare with a reagent control and an expected positive population. |
| Diffuse colour across stroma, cytoplasm, and nuclei without clear cell boundaries. | Widespread haze cannot be scored as a convincing nuclear pattern (HPA: nuclear expression in most tissues). Excess background from blocking, antibody concentration, washing, or chromogen development is possible (general IHC practice). Evaluate a control lacking primary antibody and preserve a readable counterstain when judging localization. |
| No signal in a section containing a reported high-staining cell population. | Check that the population is present: examples include cerebellar molecular layer cells and nasopharyngeal respiratory epithelial cells (HPA: High). A blank result may reflect assay failure or an antibody-specific result (general IHC practice); HPA reports medium staining–RNA consistency, so one negative section does not establish absence of MBNL1 (HPA: reliability). |
💡Expected MBNL1 appearanceCall the IHC result positive when identifiable cells show crisp nuclear staining, preferably strong in an HPA High population (HPA: tissue IHC); isolated membrane-like colour or diffuse tissue-wide haze is a suspect pattern (UniProt Q9NR56: no transmembrane segment; general IHC practice).
| Tissue and cell selection | Use an HPA High population to check a positive result, and interpret within the named cell type (HPA: tissue IHC). HPA also lists Medium glandular or hematopoietic populations, Low cardiomyocytes, and Not detected skeletal myocytes. UniProt reports high expression in cardiac and skeletal muscle (UniProt Q9NR56: tissue specificity); these source-level observations differ and should remain distinct. |
| Antibody evidence | HPA lists CAB016398 as Enhanced for IHC and HPA035098 as Supported for IHC (HPA: antibody validation). The tissue profile has Enhanced reliability but only medium staining–RNA consistency (HPA: tissue IHC). Record the antibody used before comparing staining across slides; the HPA profile does not validate every catalog antibody. |
| Cellular state | Cytoplasmic staining can be biologically plausible (UniProt Q9NR56: cytoplasm), and stress granules are reported upon stress (UniProt Q9NR56: localization with DDX1, TIAL1, YBX1). Neither observation makes granular cytoplasmic colour a routine positive IHC criterion. Assess any such pattern alongside nuclear signal and experimental context. |
| Isoforms and processing | Seven isoforms are listed, with a single protein chain from residues 1–388 and no signal peptide or propeptide (UniProt Q9NR56: isoforms, processing). These annotations do not identify the epitope recognized by the IHC antibody or predict isoform-specific staining. Interpret differences between antibodies only with their documented validation. |
| IF/ICC Q&A: What localization is expected? | Mainly nucleoplasmic fluorescence, with additional cytosolic signal, is reported (HPA: ICC-IF; nucleoplasm Enhanced, cytosol Supported). HPA lists U-251MG, A-431, and U2OS ICC-IF images (HPA: subcellular). This localization evidence can inform compartment interpretation; IF/ICC assay setup belongs in its separate guide. |
| Situation | Likely cause | Next action |
|---|---|---|
| High-staining reference cells are blank. | The reference population may be absent from the section, or an IHC workflow step may have failed (general IHC practice). | Confirm the cell type on the counterstained section, then review the catalog antibody’s IHC-P instructions, retrieval, detection reagents, and a run control (general IHC practice). Use an HPA High population as the reference (HPA: tissue IHC); no MBNL1-specific retrieval effect is established here. |
| All compartments look brown, including expected negative areas. | Non-specific background or endogenous detection activity may obscure localization (general chromogenic IHC practice). | Inspect a control lacking primary antibody; check blocking, washing, chromogen development, and the antibody dilution specified for the reagent in use (general IHC practice). Score MBNL1 only where the cellular pattern is interpretable against the reported nuclear profile (HPA: tissue IHC). |
| Only membranes or extracellular material stain. | The pattern conflicts with the reported nuclear tissue profile and protein topology (HPA: tissue IHC; UniProt Q9NR56: no transmembrane segment). | Compare an expected positive population and a control lacking primary antibody on the same run (general IHC practice). Check whether the colour follows tissue edges or deposits before calling it cellular staining; do not assign membrane localization from this slide alone. |
| Skeletal myocytes are negative despite a muscle-focused expectation. | The sources differ: UniProt describes high skeletal-muscle expression, while HPA records myocytes as Not detected in its tissue IHC survey (UniProt Q9NR56: tissue specificity; HPA: skeletal muscle). | Report the observed negative IHC result with both source annotations. Check the assay against a separate HPA High cell population (HPA: tissue IHC) before concluding that the staining run failed. |
| Cardiomyocyte staining is faint. | HPA rates cardiomyocytes Low, although UniProt describes high cardiac expression at the protein level (HPA: heart muscle; UniProt Q9NR56: tissue specificity). | Avoid treating faint cardiomyocyte signal alone as assay failure. Compare compartment and background with a High reference population in the same validated workflow (HPA: tissue IHC; general IHC practice). |
| Cytoplasmic puncta appear in an otherwise nuclear section. | Stress-associated granules are possible (UniProt Q9NR56: stress granule localization), but puncta may also reflect staining deposits (general IHC practice). | Check morphology, the control lacking primary antibody, and whether nuclei retain the expected pattern (HPA: nuclear tissue expression; general IHC practice). Describe puncta as observations; assign stress granule identity only with supporting experimental evidence. |
Experiment evidence
IHC & IF images showing MBNL1 staining
A02309-1 · IHCIHC analysis of MBNL1 using anti-MBNL1 antibody (A02309-1). MBNL1 was detected in a paraffin-embedded section of human thyroid cancer tissue
A02309-1 · IHCIHC analysis of MBNL1 using anti-MBNL1 antibody (A02309-1). MBNL1 was detected in a paraffin-embedded section of human colorectal adenocarci
A02309-1 · IFIF analysis of MBNL1 using anti-MBNL1 antibody (A02309-1). MBNL1 was detected in an immunocytochemical section of A549 cells. Enzyme antigen
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000152601-MBNL1/tissue/cerebral+cortex#imid_16530915
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000152601-MBNL1/tissue/colon#imid_16530857
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000152601-MBNL1/tissue/liver#imid_16530842
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000152601-MBNL1/tissue/kidney#imid_16530843
HPA · ICC-IF U-251MGHuman Protein Atlas immunofluorescence, U-251MG, antibody CAB016398; green = MBNL1, blue = nucleus, red = microtubules.
HPA · ICC-IF U-251MGHuman Protein Atlas immunofluorescence, U-251MG, antibody CAB016398; green = MBNL1, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for MBNL1 IHC & IF
🧪Run skin first: arrector pili muscle cells should stain (HPA: High in arrector pili muscle cells). Use adipose tissue as the negative tissue; where adipocytes are present on the skin section, they should lack specific staining and provide an internal negative reference (HPA: Not detected in adipocytes).
Positive control tissue: Cerebellum (Cells in molecular layer, HPA High)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show MBNL1 in U-251MG, A-431, U2OS, with annotated localisation: Nucleoplasm (enhanced) (HPA subcellular).
Technical controls: Include no-primary (secondary-only) and concentration-matched rabbit isotype controls, plus MBNL1 knockout tissue or a peptide-block control if the immunizing peptide is available (caption: rabbit anti-MBNL1 antibody). Block endogenous peroxidase and distinguish skin pigment from DAB signal when assessing the positive section (standard chromogenic IHC practice; HPA: High in skin arrector pili muscle cells).
⚠️Feasibility: A target-specific fixation window and fixation effect are unreported, and the selected A02309-1 paraffin-section caption does not state a fixative (caption: fixative not stated). Heat retrieval in EDTA at pH 8.0 is documented for the catalog antibody, but retrieval dependence has not been established (caption: heat-mediated EDTA retrieval). The supplied evidence does not establish that frozen sections or IF are easier; skin pigment may complicate DAB interpretation (caption: paraffin-section DAB detection; standard chromogenic IHC practice).
HPA tissue IHC evidence for MBNL1
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Enhanced — Medium consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Cerebellum | Cells in molecular layer | High | Protein (IHC) | HPA → |
| Nasopharynx | Respiratory epithelial cells | High | Protein (IHC) | HPA → |
| Skin | Arrector pili muscle cells | High | Protein (IHC) | HPA → |
| Testis | Spermatogonia cells | High | Protein (IHC) | HPA → |
| Adrenal gland | Glandular cells | Medium | Protein (IHC) | HPA → |
Section 3
Advanced MBNL1 IHC Tips
Troubleshoot MBNL1 staining in paraffin sections by checking retrieval, cellular localisation, antibody specificity and scoring within defined cell populations.
Which retrieval condition should I try first for weak MBNL1 staining?
Use heat-mediated antigen retrieval in EDTA at pH 8.0 for paraffin sections (datasheet A02309-1). The catalog antibody detected MBNL1 in a paraffin-embedded human thyroid cancer section after that retrieval step, although the caption gives no heating time (datasheet A02309-1). Keep section thickness, heating and cooling consistent across comparison slides, then check whether nuclei become clearer without excess tissue damage (standard IHC practice; HPA: nuclear expression in most tissues). If staining remains weak, optimise retrieval duration on matched sections before testing another buffer as a fallback (standard IHC practice). Record each condition alongside the catalog antibody concentration of 2 μg/ml used in the example (datasheet A02309-1).
Could fixation explain weak or uneven MBNL1 staining?
Target-specific fixation sensitivity is unknown: the catalog paraffin-section caption does not state its fixative (datasheet A02309-1). Compare sections with documented, matched fixation histories before attributing a staining difference to MBNL1 abundance (standard IHC practice). Excessive or uneven fixation can affect antigen accessibility and morphology in IHC generally, so inspect both alongside staining rather than assigning MBNL1 a particular fixation response (standard IHC practice). Keep retrieval at EDTA pH 8.0 and the starting antibody concentration at 2 μg/ml while investigating fixation as a variable (datasheet A02309-1). A reproducible difference under controlled processing supports a technical explanation, but does not establish this antigen's fixation threshold (standard IHC practice).
Should MBNL1 staining be nuclear or cytoplasmic?
Expect predominantly nuclear staining in routine tissue IHC: the tissue profile reports nuclear expression in most tissues (HPA: tissue IHC profile). Nucleoplasmic localisation is the main subcellular finding, while cytosolic localisation is also supported (HPA: subcellular). MBNL1 can occupy cytoplasmic stress granules under stress and nuclear foci with retained expanded-repeat transcripts in affected myotubes, so discrete nonnuclear or punctate signal needs biological context (UniProt Q9NR56: subcellular location). Score nuclear and cytoplasmic staining separately within the same identified cell type, with a counterstain to anchor compartment calls (standard IHC practice). Predominantly sharp membrane outlines warrant specificity checks because MBNL1 has no annotated transmembrane segment (UniProt Q9NR56: topology).
Could the antibody epitope or MBNL1 isoforms change my IHC result?
MBNL1 has 7 listed isoforms, but the supplied catalog caption does not identify the antibody epitope or establish which isoforms it detects (UniProt Q9NR56: isoforms; datasheet A02309-1). Do not interpret a staining difference between tissues as an isoform switch without an isoform-resolved validation method (standard IHC interpretation). The record notes phosphothreonine at residue 6 and no annotated glycosylation sites, but neither fact establishes whether this antibody recognises a modified epitope (UniProt Q9NR56: modified residues and glycosylation). If epitope coverage matters, obtain the immunogen sequence and compare it with the isoforms before assigning specificity (standard antibody validation practice). Keep retrieval and detection conditions matched during that comparison (standard IHC practice).
How can I check MBNL1 localisation with multiplex IF?
For the separate IF/ICC workflow, pair MBNL1 with a validated marker of the expected cell type, such as arrector pili muscle cells, and include a nuclear counterstain (HPA: high staining in arrector pili muscle cells; standard IF practice). Choose spectrally separated fluorophores and assess unstained tissue for autofluorescence before interpreting cytoplasmic puncta (standard IF practice). Permeabilise sufficiently to reach nuclear and cytosolic epitopes; MBNL1 has no transmembrane segment, while this antibody's epitope position is unspecified (UniProt Q9NR56: topology; datasheet A02309-1). Compare nuclear signal with the counterstain and report cytosolic signal separately (HPA: nucleoplasm enhanced, cytosol supported). Optimise IF staining independently of the catalog paraffin-section IHC conditions (datasheet A02309-1; standard IF practice).
How do I reduce diffuse brown background without losing MBNL1 signal?
First compare a no-primary control with the stained section to separate detection-system background from antibody-associated signal (standard IHC practice). The catalog example used 10% goat serum blocking, 2 μg/ml primary antibody overnight at 4°C, and a peroxidase-conjugated secondary for 30 minutes at 37°C (datasheet A02309-1). If background persists, titrate the primary antibody and improve washing while holding retrieval and development conditions constant (standard IHC practice). Include an endogenous peroxidase block and control DAB development time as general chromogenic workflow steps, particularly when brown signal appears without primary antibody (standard IHC practice). Preserve identifiable nuclear staining when judging whether a change improves the assay (HPA: nuclear expression in most tissues).
What should I measure when MBNL1 staining varies across sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population and anatomical region before scoring, then record nuclear and cytoplasmic MBNL1 separately (standard IHC practice; HPA: nuclear expression in most tissues). For nuclear staining, use the percentage of positive nuclei or an H-score: multiply each intensity category, 0–3, by its percentage of cells and sum to 0–300 (standard IHC scoring practice). Normalise cell counts to all evaluable nuclei of the same cell type; normalise density measures to sampled tissue area in mm² (standard IHC quantification practice). Apply one threshold and exposure-independent chromogenic scoring rule across the batch (standard IHC practice). Report cell types separately because the tissue profile includes both high and undetected populations (HPA: tissue IHC profile).
How can I distinguish true MBNL1 staining from artefact?
A credible result has interpretable cell morphology and a compartment pattern consistent with chiefly nuclear MBNL1, allowing some cytoplasmic signal (HPA: tissue IHC and subcellular profiles). Check whether staining follows the expected cell population: high signal is reported in arrector pili muscle cells, whereas skeletal myocytes were undetected in the cited tissue profile (HPA: skin and skeletal muscle). Sharp section-edge staining, necrotic regions and brown deposits in a no-primary control call for technical review before biological interpretation (standard IHC practice). Investigate predominantly membrane-like staining because MBNL1 has no annotated transmembrane segment (UniProt Q9NR56: topology). Reconcile unexpected results with matched processing, antibody controls and cell-specific scoring rather than treating one field as definitive (standard IHC practice).
Boster reagents
Best MBNL1 / Muscleblind-like protein 1 IHC Antibodies
A02309-1 has IHC images from human paraffin tissue and IF images from A549 cells and human paraffin tissue (catalog image captions); listed reactivity spans human, monkey, mouse and rat (catalog applications/reactivity).
Real IHC data
Anti-MBNL1 Antibody ®
Cat # A02309-1
A02309-1 will render with an IHC image from a human thyroid cancer paraffin section (catalog IHC caption). The same SKU lists IHC, IF and ICC applications and has IF images from A549 cells and human colon cancer paraffin tissue (catalog applications; IF captions).
Which to pick: Choose A02309-1 for paraffin tissue IHC: its image caption documents EDTA retrieval at pH 8.0 and primary antibody at 2 μg/ml in a human thyroid cancer section; the fixative is unreported (catalog IHC caption). For IF/ICC, A02309-1 has images from A549 cells and human colon cancer paraffin tissue, with primary antibody at 5 μg/ml (catalog IF captions). For cross-species work, A02309-1 lists human, monkey, mouse and rat reactivity, while its supplied IHC and IF images show human samples (catalog reactivity; image captions).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q9NR56 (MBNL1_HUMAN, Muscleblind-like protein 1).
- Human Protein Atlas. MBNL1 tissue IHC expression (reliability: Enhanced).
- Human Protein Atlas. MBNL1 subcellular location (ICC-IF): Mainly localized to the nucleoplasm. In addition localized to the cytosol..
- Human Protein Atlas. MBNL1 antibody validation summary (2 antibodies).
- Comparative Proteomic Analysis of tPVAT during Ang II Infusion. Biomedicines 2021 — PMC8698607.
- The Alternative Splicing Factor, MBNL1, Inhibits Glioblastoma Tumor Initiation and Progression by Reducing Hypoxia-Induced Stemness. Cancer research 2020 — PMC7642170.
- Muscleblind-like 1 is required for normal heart valve development in vivo. BMC developmental biology 2015 — PMC4608261.
- MBNL1 Promotes Intestinal Fibrosis via RAS-MAPK Pathway-Mediated Fibroblast Activation and Proliferation. Biomedicines 2026 — PMC13297613.
- PubMed PMID:9455477 — UniProt-cited evidence.
- PubMed PMID:10970838 — UniProt-cited evidence.
- PubMed PMID:11590133 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for MBNL1 (Muscleblind-like protein 1). Expected localisation Nuclear tissue staining; cytoplasmic location also annotated (HPA tissue IHC; UniProt). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet A02309-1). Validated IHC antibody: A02309-1 at 2-5μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Cerebellum (Cells in molecular layer); negative Adipose tissue. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human thyroid cancer tissue; fixative not specified (datasheet A02309-1); 2. Fixation: Image fixative and duration unreported (datasheet A02309-1); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet A02309-1); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet A02309-1); 8. Primary antibody: Rabbit anti-MBNL1, 2-5μg/ml (datasheet A02309-1); 9. Primary incubation: Overnight at 4 °C (datasheet A02309-1). Watch for: Fixation: Keep fixation consistent across paraffin sections. (standard IHC practice; not target-specific); Caveat: Skeletal myocytes may lack staining despite reported muscle expression (HPA tissue IHC; UniProt); Isoform / epitope: 7 isoforms; antibody epitope coverage is unspecified (UniProt; datasheet A02309-1); Regulation: Higher during myoblast differentiation (UniProt). Evidence: UniProt Q9NR56, HPA tissue IHC · Enhanced, HPA ICC-IF · Mainly localized to the nucleoplasm. In addition localized to the…, Datasheet A02309-1, PMC8698607, PMC7642170. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/MBNL1/immunohistochemistry-ihc-guide.